Multiprofile Hospital For Active Treatment Sveti Ivan Rilski 2003 OOD

The Internal Diseases Department is conducting research on a range of cardiovascular conditions, including ischemic stroke, heart failure with renal involvement, and hypertension in patients with type 2 diabetes. Trials aim to test new anticoagulant strategies, evaluate combined SGLT2‑inhibitor therapies, and assess interventions that may lower the risk of cardiovascular death.

• Evaluation of novel anticoagulant agents for stroke prevention
• Assessment of combined SGLT2‑inhibitor regimens in heart failure
• Investigation of renal outcomes in patients with chronic kidney disease
• Study of lipid‑lowering therapies for hyperlipidemia
• Exploration of blood pressure management in high‑risk populations

Multiprofile Hospital For Active Treatment Sveti Ivan Rilski 2003 OOD hosts a multidisciplinary team of seven investigators who are driving these cardiovascular studies forward.

Research efforts focus on asthma and chronic obstructive pulmonary disease (COPD), targeting patients whose symptoms remain uncontrolled despite standard therapy. The goal is to improve lung function, reduce exacerbations, and evaluate the safety of emerging inhaled combinations and biologic treatments.

• Inhaled triple therapy efficacy in severe asthma
• Reduction of COPD exacerbations with novel agents
• Safety assessment of new monoclonal antibodies for airway inflammation
• Pediatric evaluation of antibiotic therapy for respiratory infections
• Comparative studies of maintenance versus rescue inhaler strategies

The department’s respiratory program benefits from the hospital’s central location in Dupnitsa, facilitating patient recruitment across the region.

Trials address disorders of the gastrointestinal tract such as gastroesophageal reflux disease (GERD) with erosive esophagitis, as well as metabolic liver conditions like alcoholic liver disease and metabolic dysfunction‑associated steatotic liver disease. Studies aim to compare acid‑suppression agents, evaluate liver‑protective formulations, and improve outcomes for chronic viral hepatitis.

• Healing of erosive esophagitis with new proton‑pump inhibitors
• Management of metabolic liver disease using nutraceuticals
• Treatment strategies for chronic hepatitis B infection
• Comparative effectiveness of acid‑suppression therapies
• Supportive care approaches for alcoholic liver disease

The hospital’s gastroenterology team collaborates closely with internal medicine specialists to ensure comprehensive care for these conditions.

The site is evaluating therapies for serious bacterial infections, notably complicated urinary tract infection and acute pyelonephritis, including pediatric populations. Research focuses on safety, tolerability, and efficacy of new intravenous antimicrobial combinations against resistant pathogens.

• Intravenous antibiotic safety in children with urinary infections
• Efficacy of novel antimicrobial agents against resistant uropathogens
• Pharmacokinetic profiling of combination therapy in pediatric patients
• Evaluation of infection‑related outcomes in hospitalized adults
• Monitoring of adverse events for new antimicrobial regimens

With seven investigators overseeing the program, the department contributes valuable data on infection management to the broader European clinical research network.